undamentalytics Newsletter
Sign in

Cervomed Inc. income statement

In fiscal 2025, Cervomed Inc. reported revenue of $4.0m, down 58.9% on the year before, operating income of −$28.3m (a -706.2% margin) and net income of −$27.0m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112012Dec 20122013Dec 20132022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0100071040
Cost of revenue0200—————
Gross profit−0−200—————
Research and development—0—018192221
General and administrative27572791010
Operating income−8−16−12−13−3−8−18−28−31
Interest expense00−0000———
Income before tax———−3−16————
Income tax——000——0—
Net income−8−23−7−2−6−2−16−27−30
Diluted EPS−$4.67−$8.67−$2.72−$0.03$135926.07———−$3.19
Diluted shares (average)2m3,031m3,366m8m8m8m8m9m10m
EBITDA−8−16−12−13−3————

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CRDF vs CRVOCLNN vs CRVOCLDX vs CRVO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cervomed Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cervomed Inc.